

Supplemental Table A: Net secretion & CKD correlates – Comparing low (Cat 1), medium (Cat 2), and high (Cat 3) cinnamoylglycine clearance, for subjects with same average Ur-Cr clearance

Characteristics, mean(SD) unless noted	Category 1 (Low) N=98	Category 2 (Medium) N=99	Category 3 (High) N=99	P for trend
Age, years	60.5 (14.5)	59.5 (14.5)	59.0 (12.0)	0.75
Male gender, n(%)	67 (69.1%)	82 (82.8%)	85 (85.0%)	0.01
Black race, n(%)	21 (21.6%)	29 (29.3%)	28 (28.0%)	0.43
Other non-white race, n(%)	13 (13.4%)	8 (8.1%)	6 (6.0%)	0.18
Urea-creatinine clearance, mL/min	54.6 (30.6)	55.1 (38.2)	53.2 (27.7)	0.92
Daily creatinine excretion / lean body mass, mg/kg <sup>†</sup>	31.0 (12.8)	30.8 (12.8)	30.5 (11.0)	0.96
Estimated GFR, mL/min/1.73m <sup>3</sup> <sup>†</sup>	48.3 (28.1)	46.4 (26.7)	47.9 (23.6)	0.87
Body mass index, kg/m <sup>2</sup>	31.5 (7.7)	31.5 (7.2)	32.0 (7.7)	0.87
Systolic blood pressure, mmHg	132.6 (22.2)	130.9 (20.7)	129.4 (20.1)	0.55
Current smoking, n(%)	16 (16%)	17 (17%)	24 (24%)	0.29
Current alcohol use, n(%)	23 (23.7%)	32 (32.3%)	39 (39.0%)	0.07
Medications use:				
Aspirin, n(%)	34 (35.1%)	38 (38.4%)	45 (45.0%)	0.35
Statin, n(%)	49 (50.5%)	54 (54.5%)	63 (63.0%)	0.20
H2 blocker, n(%)	8 (8.2%)	10 (10.1%)	9 (9.0%)	0.90
Loop diuretic, n(%)	42 (43.3%)	40 (40.4%)	36 (36.0%)	0.57
Thiazide, n(%)	12 (12.4%)	15 (15.2%)	16 (16.0%)	0.75
ACE inhibitor, n(%)	55 (56.7%)	50 (50.5%)	59 (59.0%)	0.46
Angiotensin-R blocker, n(%)	36 (37.1%)	40 (40.4%)	35 (35.0%)	0.73
Colchicine, n(%)	7 (7.2%)	4 (4.0%)	6 (6.0%)	0.63
EPO, n(%)	3 (3.1%)	6 (6.1%)	4 (4.0%)	0.58
Insulin, n(%)	25 (25.8%)	26 (26.3%)	28 (28.0%)	0.93
Oral diabetes medication, n(%) <sup>†</sup>	21 (21.6%)	18 (18.2%)	21 (21.0%)	0.81
Prevalent diabetes, n(%) <sup>†</sup>	50 (51.5%)	52 (52.5%)	55 (55.0%)	0.88
Prevalent cardiovascular disease, n(%) <sup>†</sup>	8 (8.2%)	12 (12.1%)	5 (5.0%)	0.19
Laboratory measures:				
Hemoglobin A1c, %	6.7 (1.9)	6.4 (1.4)	6.5 (1.2)	0.26
Cholesterol, mg/dL	174.4 (61.5)	176.6 (59.1)	162.8 (44.2)	0.17
C-Reactive Protein, mg/L	5.9 (10.7)	5.1 (6.6)	5.8 (8.0)	0.77
CO2 (bicarbonate), mmol/L	24.5 (3.6)	24.8 (3.7)	25.0 (3.3)	0.60
Fractional excretion Phosphorus, %	29.4 (13.0)	31.4 (16.3)	27.3 (19.0)	0.21
Fractional excretion Uric Acid, %	6.9 (3.9)	7.6 (4.2)	6.5 (6.7)	0.30
Fractional excretion Calcium, %	1.3 (1.3)	1.5 (2.5)	1.1 (1.2)	0.40
Fractional excretion Sodium, %	1.6 (1.4)	1.7 (1.4)	1.5 (1.5)	0.38
Fractional excretion Potassium, %	17.3 (16.5)	14.9 (9.4)	12.5 (7.5)	0.02
Albumin excretion rate, mg/d, med(IQR)	209 (27, 810)	161 (17, 963)	159 (20, 1124)	0.62 <sup>‡</sup>

<sup>†</sup> Oral diabetes medications metformin or sulfonylurea; prevalent diabetes based on self-report, physician diagnosis, use of DM medications, or fasting glucose; cardiovascular disease (CVD) defined as coronary artery disease (CAD), heart failure (HF), peripheral vascular disease (PWD), or cerebrovascular disease (CBVD)

<sup>‡</sup>Test for trend of median AER over categories of clearance based on quantile regression.

Supplemental Table B: Net secretion & CKD correlates – Comparing low (Cat 1), medium (Cat 2), and high (Cat 3) P-cresol sulfate clearance, for subjects with same average Ur-Cr clearance

Characteristics, mean(SD) unless noted	Category 1 (Low) N=95	Category 2 (Medium) N=97	Category 3 (High) N=97	P for trend
Age, years	58.23 (13.71)	59.99 (13.82)	60.86 (14.09)	0.41
Male gender, n(%)	72 (76%)	80 (82%)	75 (77%)	0.50
Black race, n(%)	25 (26%)	23 (24%)	29 (30%)	0.62
Other non-white race, n(%)	7 (7%)	11 (11%)	9 (9%)	0.64
Urea-creatinine clearance, mL/min	52.89 (30.13)	53.43 (32.17)	54.19 (32.01)	0.96
Daily creatinine excretion / lean body mass, mg/kg <sup>†</sup>	29.85 (11.52)	30.48 (11.14)	31.18 (13.42)	0.75
Estimated GFR, mL/min/1.73m <sup>3</sup> <sup>†</sup>	48.26 (27.85)	45.83 (24.88)	47.88 (26.38)	0.79
Body mass index, kg/m <sup>2</sup>	31.03 (7.34)	31.96 (7.74)	31.99 (7.72)	0.61
Systolic blood pressure, mmHg	129.65 (20.64)	129.81 (19.26)	134.46 (23.27)	0.20
Current smoking, n(%)	17 (18%)	18 (19%)	20 (21%)	0.90
Current alcohol use, n(%)	34 (36%)	31 (32%)	25 (26%)	0.32
Medications use:				
Aspirin, n(%)	32 (34%)	42 (43%)	43 (44%)	0.25
Statin, n(%)	49 (52%)	58 (60%)	56 (58%)	0.49
H2 blocker, n(%)	11 (12%)	8 (8%)	7 (7%)	0.54
Loop diuretic, n(%)	34 (36%)	40 (41%)	45 (46%)	0.33
Thiazide, n(%)	14 (15%)	12 (12%)	15 (15%)	0.81
ACE inhibitor, n(%)	56 (59%)	55 (57%)	52 (54%)	0.76
Angiotensin-R blocker, n(%)	31 (33%)	39 (40%)	40 (41%)	0.41
Colchicine, n(%)	4 (4%)	10 (10%)	3 (3%)	0.07
EPO, n(%)	4 (4%)	3 (3%)	6 (6%)	0.57
Insulin, n(%)	25 (26%)	25 (26%)	29 (30%)	0.78
Oral diabetes medication, n(%) <sup>†</sup>	17 (18%)	19 (20%)	22 (23%)	0.70
Prevalent diabetes, n(%) <sup>†</sup>	53 (56%)	49 (51%)	53 (55%)	0.74
Prevalent cardiovascular disease, n(%) <sup>†</sup>	5 (5%)	13 (13%)	7 (7%)	0.11
Laboratory measures:				
Hemoglobin A1c, %	6.42 (1.42)	6.57 (1.56)	6.63 (1.56)	0.61
Cholesterol, mg/dL	180.38 (59.69)	168.60 (57.78)	165.36 (49.49)	0.15
C-Reactive Protein, mg/L	5.03 (7.24)	5.87 (9.09)	5.52 (8.53)	0.78
CO <sub>2</sub> (bicarbonate), mmol/L	23.88 (3.80)	25.07 (3.18)	25.44 (3.39)	0.01
Fractional excretion Phosphorus, %	31.22 (20.97)	29.94 (15.67)	27.15 (11.32)	0.22
Fractional excretion Uric Acid, %	7.76 (7.39)	7.23 (3.94)	6.11 (2.95)	0.08
Fractional excretion Calcium, %	1.65 (2.85)	1.21 (0.92)	1.02 (0.97)	0.05
Fractional excretion Sodium, %	1.90 (1.90)	1.64 (1.23)	1.31 (0.91)	0.01
Fractional excretion Potassium, %	15.34 (13.66)	15.52 (12.23)	14.43 (9.74)	0.79
Albumin excretion rate, mg/d, med(IQR)	70.73 (36.84)	63.82 (29.76)	60.19 (43.64)	0.14

<sup>†</sup> Oral diabetes medications metformin or sulfonylurea; prevalent diabetes based on self-report, physician diagnosis, use of DM medications, or fasting glucose; cardiovascular disease (CVD) defined as coronary artery disease (CAD), heart failure (HF), peripheral vascular disease (PWD), or cerebrovascular disease (CBVD)

‡Test for trend of median AER over categories of clearance based on quantile regression.

Supplemental Table C: Net secretion & CKD correlates – Comparing low (Cat 1), medium (Cat 2), and high (Cat 3) Indoxyl sulfate clearance, for subjects with same average Ur-Cr clearance

Characteristics, mean(SD) unless noted	Category 1 (Low) N=95	Category 2 (Medium) N=98	Category 3 (High) N=96	P for trend
Age, years	57.40 (14.14)	60.57 (14.80)	60.86 (12.47)	0.16
Male gender, n(%)	70 (74%)	84 (86%)	73 (76%)	0.10
Black race, n(%)	22 (23%)	21 (21%)	33 (34%)	0.09
Other non-white race, n(%)	8 (8%)	13 (13%)	6 (6%)	0.23
Urea-creatinine clearance, mL/min	53.77 (33.73)	53.55 (32.15)	54.27 (31.64)	0.99
Daily creatinine excretion / lean body mass, mg/kg <sup>†</sup>	29.52 (11.27)	31.70 (11.41)	30.68 (13.82)	0.46
Estimated GFR, mL/min/1.73m <sup>3</sup> <sup>†</sup>	49.79 (30.00)	43.58 (24.08)	48.85 (24.74)	0.21
Body mass index, kg/m <sup>2</sup>	31.08 (7.21)	30.67 (7.27)	33.10 (8.07)	0.06
Systolic blood pressure, mmHg	129.95 (21.37)	130.56 (19.47)	133.40 (22.49)	0.48
Current smoking, n(%)	16 (17%)	19 (19%)	21 (22%)	0.72
Current alcohol use, n(%)	35 (37%)	31 (32%)	26 (27%)	0.35
Medications use:				
Aspirin, n(%)	31 (33%)	35 (36%)	51 (53%)	0.01
Statin, n(%)	49 (52%)	53 (54%)	60 (63%)	0.28
H2 blocker, n(%)	11 (12%)	8 (8%)	7 (7%)	0.55
Loop diuretic, n(%)	31 (33%)	38 (39%)	49 (51%)	0.03
Thiazide, n(%)	11 (12%)	16 (16%)	14 (15%)	0.63
ACE inhibitor, n(%)	58 (61%)	50 (51%)	53 (55%)	0.37
Angiotensin-R blocker, n(%)	30 (32%)	41 (42%)	38 (40%)	0.31
Colchicine, n(%)	6 (6%)	7 (7%)	4 (4%)	0.66
EPO, n(%)	4 (4%)	4 (4%)	5 (5%)	0.92
Insulin, n(%)	23 (24%)	25 (26%)	30 (31%)	0.51
Oral diabetes medication, n(%) <sup>†</sup>	16 (17%)	15 (15%)	28 (29%)	0.03
Prevalent diabetes, n(%) <sup>†</sup>	48 (51%)	49 (50%)	57 (59%)	0.34
Prevalent cardiovascular disease, n(%) <sup>†</sup>	4 (4%)	14 (14%)	7 (7%)	0.04
Laboratory measures:				
Hemoglobin A1c, %	6.31 (1.46)	6.43 (1.44)	6.84 (1.59)	0.04
Cholesterol, mg/dL	180.40 (58.77)	165.93 (56.36)	167.09 (51.64)	0.14
C-Reactive Protein, mg/L	5.21 (7.32)	4.72 (8.17)	6.52 (9.29)	0.30
CO <sub>2</sub> (bicarbonate), mmol/L	23.97 (3.70)	24.74 (3.54)	25.58 (3.13)	0.01
Fractional excretion Phosphorus, %	30.14 (21.10)	33.37 (15.72)	25.13 (9.96)	<0.01
Fractional excretion Uric Acid, %	7.87 (7.67)	7.30 (3.39)	5.92 (2.84)	0.03
Fractional excretion Calcium, %	1.68 (2.87)	1.21 (0.90)	0.97 (0.92)	0.02
Fractional excretion Sodium, %	1.85 (1.89)	1.77 (1.29)	1.24 (0.82)	0.01
Fractional excretion Potassium, %	15.13 (13.96)	16.26 (12.63)	13.84 (8.62)	0.37
Albumin excretion rate, mg/d, med(IQR)	68.84 (37.71)	68.83 (31.18)	56.73 (41.49)	0.03

<sup>†</sup> Oral diabetes medications metformin or sulfonylurea; prevalent diabetes based on self-report, physician diagnosis, use of DM medications, or fasting glucose; cardiovascular disease (CVD) defined as coronary artery disease (CAD), heart failure (HF), peripheral vascular disease (PWD), or cerebrovascular disease (CBVD)

#Test for trend of median AER over categories of clearance based on quantile regression.

Supplemental Table D: Net secretion and events comparing categories of solute clearance relative to average Urea-Creatinine clearance, with adjustment for AER

	Number of events	Incidence / 100 py (95% CI) <sup>†</sup>	Hazard ratio (95% CI) <sup>‡</sup>
<b>(A) Hippurate</b>			
Outcome: Death			
HA: Low (vs. High)	19	6.8 (3.8, 9.9)	2.5 (1.2, 5.5)
HA: Medium (vs High)	12	4.4 (2.1, 7.0)	1.1 (0.5, 2.5)
HA: High ( <i>Referent</i> )	11	3.8 (1.8, 6.6)	<i>Reference</i>
Outcome: Dialysis <sup>†</sup>			
HA: Low (vs. High)	7	2.7 (0.9, 4.8)	1.5 (0.3, 6.7)
HA: Medium (vs High)	7	2.6 (0.9, 4.8)	1.1 (0.4, 3.0)
HA: High ( <i>Referent</i> )	6	2.1 (0.7, 4.4)	<i>Reference</i>
<b>(B) Cinnamoylglycine</b>			
Outcome: Death <sup>†</sup>			
CMG: Low (vs High)	12	4.4 (2.1, 7.0)	1.0 (0.5, 2.1)
CMG: Medium (vs High)	16	5.8 (3.1, 8.7)	1.0 (0.5, 2.1)
CMG: High ( <i>Referent</i> )	15	5.1 (2.8, 8.3)	<i>Reference</i>
Outcome: Dialysis <sup>†</sup>			
CMG: Low (vs High)	9	3.5 (1.4, 5.7)	3.3 (0.7, 15.7)
CMG: Medium (vs High)	6	2.3 (0.7, 4.4)	1.1 (0.3, 4.6)
CMG: High ( <i>Referent</i> )	4	1.4 (0.4, 3.4)	<i>Reference</i>
<b>(C) P-cresol sulfate</b>			
Outcome: Death <sup>†</sup>			
PCS: Low (vs High)	14	5.6 (3.3, 9.4)	2.5 (1.0, 6.1)
PCS: Medium (vs High)	17	6.0 (3.7, 9.6)	1.3 (0.6, 3.1)
PCS: High ( <i>Referent</i> )	11	4.0 (2.2, 7.2)	<i>Reference</i>
Outcome: Dialysis <sup>†</sup>			
PCS: Low (vs High)	9	3.8 (2.0, 7.3)	0.9 (0.2, 4.0)
PCS: Medium (vs High)	7	2.5 (1.2, 5.3)	1.3 (0.3, 5.4)
PCS: High ( <i>Referent</i> )	4	1.5 (0.6, 3.9)	<i>Reference</i>
<b>(D) Indoxyl sulfate</b>			
Outcome: Death <sup>†</sup>			
IS: Low (vs High)	12	4.8 (2.7, 8.4)	1.1 (0.5, 2.5)
IS: Medium (vs High)	14	4.8 (2.8, 8.0)	0.6 (0.3, 1.3)
IS: High ( <i>Referent</i> )	16	6.0 (3.7, 9.8)	<i>Reference</i>
Outcome: Dialysis <sup>†</sup>			
IS: Low (vs High)	9	3.8 (2.0, 7.4)	1.1 (0.2, 7.1)
IS: Medium (vs High)	8	2.8 (1.4, 5.6)	1.8 (0.3, 9.7)
IS: High ( <i>Referent</i> )	3	1.1 (0.4, 3.5)	<i>Reference</i>

<sup>†</sup> 95% confidence intervals calculated from Poisson distribution.

<sup>‡</sup> Cox proportional hazards models, comparing categories of net tubular solute clearance; adjusted for age, sex, black race, other non-white race, albumin excretion rate (AER), and Ur-Cr clearance.